Navigation Links
AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
Date:4/30/2008

common stock (4,593) -

Exercise of stock options 181 17

Cash (used in) provided by financing

activities (4,412) 17

Increase (decrease) in cash and cash equivalents 4,531 (243)

Cash and cash equivalents at beginning of period 8,536 7,331

Cash and cash equivalents at end of period $13,067 $7,088

Supplemental disclosure of cash paid during

the period for:

Income taxes, net of refunds $115 $-

Non-cash investing activities:

Unrealized gain on available-for-sale securities $120 $6

2008 Projected

Reconciliation of projected net loss to Lower Upper

projected pro-forma EBITDA Range Range

Projected net loss $(1,350) $(850)

Interest income 3,000 3,000

Operating loss (4,350) (3,850)

Non-cash stock compensation expense 1,816 1,816

Depreciation and amortization 1,286 1,286

Amortization of software development costs 2,286 2,286

Projected pro-forma EBITDA $1,038 $1,538

Reconciliation of net (loss) income to Three Months Ended

pro-forma EBITDA March 31,

2008 2007

Net (loss) income $(467) $146

Provision for income taxes (61) (62)

Interest income
'/>"/>

SOURCE AMICAS, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. AMICAS to Present at CIBC World Markets 18th Annual Healthcare Conference
2. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
3. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
4. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
5. Alexion Reports First Quarter 2008 Results
6. Masimo Reports First Quarter 2008 Financial Results
7. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
8. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
9. SuperGen Reports 2008 First Quarter Financial Results
10. Emisphere Reports Receipt of Notification from NASDAQ Regarding Non-Compliance with Continued Listing Requirements
11. Gen-Probe Reports Strong Financial Results for First Quarter 2008, Raises Full-Year Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2008)... new therapies based on cells manufactured from ...e funding round, SALT LAKE CITY and HAMBURG, Germ...chnology company at the forefront of innovative ce...ury, today announced the closing of a,$14.5MM Seri...ces with Novo,A/S joining the syndicate., "This f...
(Date:7/2/2008)...re/ -- Aureus Pharma, a leading provider of,knowle...n the life science,industry, announced today that ... in Paris on October 23rd and 24th., This symposi... event,which was attended by many of Aureus, pharm...nd North America. The symposium included presentat...
(Date:7/2/2008)...ercialization of Expanded Portfolio of Vascular ... British Columbia, July 2 /- Neovasc ...(TSXV: MEV), a company developing and,marketing in...ed its name,change and the expansion of its produc...ion of two vascular product development companies ...
(Date:7/2/2008)...ential of pre-treatment R2 levels as a possible ... TORONTO, July 2 / Lorus T... the "Corporation"), a biopharmaceutical company,s...rmaceutical products and,technologies for the mana...n Ohio State University (OSU) clinical team of a p...
Breaking Biology Technology:AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 2AlloCure Inc. Closes $14.5MM Series A Round to Develop a Stem Cell Therapy for Acute Kidney Injury 3Aureus Pharma Announces Date of 2008 Annual User Symposium 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 2Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 3Medical Ventures Becomes Neovasc with Two Corporate Acquisitions and $8.3 Million Financing 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 2Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 3Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 4Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML) 5
...Molly Jahn is a realist, and she,s telling anyone ...nce to lead the drive toward energy independence. ...gricultural and Life Sciences (CALS) at the Univ...sin can leverage existing economies and industries... aware of criticism that Wisconsin (and the nation...
...Tucked away on page 417 of the executive budget bo...uced this week by Gov. Jim Doyle is another atte... online purchases of digital content. , ,The propo...sal died at the committee level in a Republican co...ying field for traditional music stores. But an op...
... using technology efficiently? Protecting customer...s? More importantly, is there strong communication...logy decisions are being made with business needs ...ependent on information technology (IT) to become ...ate. But for IT to help, not hinder, a company in ...
...- Johnson Controls , responding to increasing glo...nced the launch of a new business division to deve...e company,s new renewable technologies unit will f...r alternative sources of energy. , ,Johnson Cont...e forms of energy from businesses and other organi...
Other Biology Technology:UW-Madison dean predicts bio-economy will fuel Wisconsin 2UW-Madison dean predicts bio-economy will fuel Wisconsin 3Doyle wants sales tax applied to digital downloads 2Doyle wants sales tax applied to digital downloads 3Are your business and technology goals aligned? 2Are your business and technology goals aligned? 3
(Date:7/2/2008)...want to produce a lot of a substance -- such as a ...s, molecules that speed chemical reactions. Many j...ing one in just the right shape to connect with ce...s, such as enzymes in the human body that help us ...ting to suit the task at hand. , Chemists have m...
(Date:7/2/2008)...erman . , Metabolomics aims to determine the tot.... The exponents of bioinformatics analyzed data co...omics study in healthy and diabetic mice. In each ...he diabetes drug RoziglitazoneTM. Then, more than ...a blood plasma sample of a total of forty mice, re...
(Date:7/2/2008)...Spanish . , Most of the functions performed by ...eins, which recognise their binding partner by aff...here are many kinds of interactions; however, the ...structural biology are those which are transient. ...gh a large section of the protein surface- the glo...
(Date:7/2/2008)... of its kind, using sophisticated methods to measu...al weight loss program, Weight Watchers, was compa...ethod wins in the game of good health. A Universit...periences of participants to determine which progr...ain health benefits. The answer is that both have ...
Breaking Biology News(10 mins):Synthetic molecules emulate enzyme behavior for the first time 2Synthetic molecules emulate enzyme behavior for the first time 3Healthy or diseased? 2Scientists reveal the key mechanisms for affinity between transient binding proteins 2Weight Watchers vs. fitness centers 2Queens University launches UKs first Center of Excellence for Public Health 3684 1Queens University launches UKs first Center of Excellence for Public Health 3684 2Dynamin drug discovery team win prestigious international epilepsy grant 22180 1Dynamin drug discovery team win prestigious international epilepsy grant 22180 2Dynamin drug discovery team win prestigious international epilepsy grant 22180 3Zix Corporation Processes More Than 20 Million Electronic Prescriptions 22175 1Zix Corporation Processes More Than 20 Million Electronic Prescriptions 22175 2Zix Corporation Processes More Than 20 Million Electronic Prescriptions 22175 3Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 22170 1Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 22170 2Philips Web Site Offers Seniors and Caregivers Tips and Techniques for Preventing Falls 22170 3
...ithin only three months after deciding to create a... clinical trial registry and results database usin...rials.com information on Roche’s clinical trials c...rd restrictions. This site is designed to give pat...ormation they need, in terms they can understand. ...
...oreign species, such as zebra mussels and carp, ar...y of this vital ecosystem. A study from McMaster U...nal of Great Lakes Research suggests that for the ...eir ability to wrest territory from native fish pl...es. , In the study, McMaster,s Sigal Balshine, an ...
...iomedical engineers at Duke University,s Pratt Sch...ional ultrasound cardiac imaging probe. Inserted i...f the whole heart in the time it takes for current...ss section. , The new probe has considerable poten...heart, but also for use in guiding therapeutic tre...
...he complexity of the brain and, more specifically,...ere are fewer than 30,000 human genes is still a s...iesinger and Hugo J. Bellen at Baylor College of M...puzzle by finding a gene that plays a key role in ... in the journal Neuron. , "We were surprised to f...
Other Biology News:Roche clinical trial registry and results database launched 2Roche clinical trial registry and results database launched 3Duke engineers develop new 3-D cardiac imaging probe 2
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications).
Cultured human omental preadipocytes are isolated from obese but otherwise healthy donors. There is limited availability of diabetic cells. Please inquire for more information. Support media also ava
Anti-Flavocytochrome b Monoclonal, FITC Labeled Research Focus: other Storage: 4C Shipping Temperature: 4C
Yields DNA greater than 50 kb in length from yeast, fungi, Gram neg. and Gram pos. bacteria
Biology Products: